Advancedmolecular

DNA Methylation

Overview

DNA methylation (5-methylcytosine, 'the fifth base') occurs at CpG dinucleotides in mammals: ~70-80% methylated genome-wide, but CpG islands at promoters are usually unmethylated when genes are active. DNMT3A/3B establish marks, DNMT1 maintains them, TET enzymes remove them. Methylation silences transposons, enables imprinting and X-inactivation, and its disruption drives cancer.

Learning objectives

  • Describe CpG methylation patterns
  • Explain DNMT and TET enzyme functions
  • Describe how methylation silences genes
  • Explain methylation in development and cancer

The CpG landscape

Mammalian genomes are CpG-poor (deamination of methyl-C over evolution) except CpG islands: dense clusters at ~60% of promoters. Methylated island = silent promoter; unmethylated = permissive. Global methylation silences transposons and repetitive DNA that threaten genome stability.

Islands at promoters

CpG island methylation status is the on/off switch read at most gene promoters.

The enzyme cycle

DNMT3A/3B: de novo methylation (development, imprinting). DNMT1: maintenance at replication, copying marks to daughter strands. TET1/2/3: oxidize 5mC to 5hmC/5fC/5caC, leading to active demethylation. 5hmC is also a stable mark in neurons with its own readers.

TET needs vitamin C

TET enzymes are Fe(II)/alpha-KG dioxygenases enhanced by ascorbate: metabolism meets epigenetics.

How methylation silences

Directly: methyl groups block some transcription factors. Indirectly: MBD proteins (MeCP2, MBD2) bind methyl-CpG and recruit HDACs/corepressors, compacting chromatin. Either route converges on a closed, silent locus.

Methylation is not always repressive

Gene-body methylation correlates with ACTIVE transcription; context (promoter vs body) decides.

Development and disease

Two waves of demethylation/remethylation reprogram the germline and early embryo. In cancer: global hypomethylation (instability, oncogene activation) plus focal tumor-suppressor hypermethylation (p16, MLH1, BRCA1). Liquid-biopsy methylation panels now detect cancers from blood.

Methylation as cancer biomarker

Tumor-specific methylation patterns in cell-free DNA enable multi-cancer early detection tests.

Key points

  • 5-methylcytosine at CpGs; islands at promoters switch genes off when methylated
  • DNMT3s establish, DNMT1 maintains, TETs remove
  • Silencing via TF blocking and MBD-recruited chromatin compaction
  • Reprogrammed in embryo; disrupted in cancer (biomarker opportunity)

Common misconceptions

✗ Myth: Methylation always silences genes.

✓ Truth: Promoter methylation silences, but gene-body methylation marks active transcription: location matters.

✗ Myth: Methylation patterns are permanent.

✓ Truth: TET-mediated demethylation actively rewrites them, especially in development and neurons.

Practice questions

Q1. Maintenance DNA methylation is performed by
  1. DNMT3A
  2. DNMT1
  3. TET2
  4. MBD2
Answer: B.

DNMT1 copies methylation patterns to daughter strands during replication.

Q2. CpG island hypermethylation at a tumor-suppressor promoter causes
  1. Activation
  2. Silencing of the tumor suppressor
  3. Nothing
  4. Amplification
Answer: B.

Methylation recruits MBD proteins and HDACs, closing the promoter.

Q3. TET enzymes function to
  1. Add methyl groups
  2. Oxidize 5mC toward demethylation
  3. Bind RNA
  4. Cut DNA
Answer: B.

TETs convert 5mC to 5hmC/5fC/5caC, enabling active demethylation.

Click a question to reveal the answer and explanation.

Frequently asked questions

Why are CpG islands unmethylated at active promoters?

Transcription factor binding and protective factors (like CXXC proteins) exclude DNMTs; methylation would recruit silencers.

What is 5hmC?

5-hydroxymethylcytosine: TET's first oxidation product, abundant in brain, both a demethylation intermediate and a functional mark.

How does azacitidine work?

This cytosine analog incorporates into DNA and traps DNMTs, causing passive demethylation and reactivating silenced genes.